Refine by
Applications
- Prefilled Syringes and Combination Products for Nitrogen Dioxide Gas Sterilization
- Endoform - Antimicrobial and Natural Restorative Bioscaffold for Negative Pressure Wound Therapy
- Solution for Clinical Trials
- Solution for Access to Investigational Medicines
- Remote Patient Monitoring Solution for Remote Patient Monitoring
- Remote Patient Monitoring Solution for Revenue Cycle Management
- Remote Patient Monitoring Solution for EHR Integration
Cytotoxic Equipment & Supplies
400 equipment items found
by:Nelson Laboratories, LLC based inSalt Lake City, UTAH (USA)
Cytotoxicity: Agar overlay, L929 cells, 24 hrs. ...
by:Nelson Laboratories, LLC based inSalt Lake City, UTAH (USA)
Cytotoxicity: MEM elution, 48 hr inc., L929, 24 hr ext ...
by:Nelson Laboratories, LLC based inSalt Lake City, UTAH (USA)
Cytotoxicity: MEM elution, 48 hr inc., L929, 72 hr ext ...
Manufactured by:Envair Technology based inHeywood, UNITED KINGDOM
Envair Technology's CDC F Negative Pressure Isolator is designed to safeguard pharmacy and laboratory professionals from hazardous exposure to cytotoxic drugs while ensuring microbiological contamination prevention. It provides versatility with options for two or four glove configurations and customizable working areas, enhancing operational ease. These isolators are equipped ...
Manufactured by:Tevogen Bio based in, NEW JERSEY (USA)
Innovative Science in Virology, Oncology, and Neurology; Allogeneic CD8+ T cell therapies from a single donor to treat thousands for the first ...
Manufactured by:Eutilex Co.,Ltd. based inSeoul, SOUTH KOREA
Fully humanized anti-human 4-1BB monoclonal antibody. Agonistic effect of EU101 promotes cytotoxic T lymphocyte response and it leads to eradication of ...
Manufactured by:ACS Biotech based inVilleurbanne, FRANCE
Biocompatibility, control of bioresorbability , non-cytotoxic degradation products, fungistatic, antibacterial, good cell adhesion, promotion of chondrogenesis, regeneration of the target ...
Manufactured by:Mablink Bioscience based inLyon, FRANCE
Most of the challenges of ADCs are linked to the hydrophobicity of the cytotoxic drugs used, which degrade the pharmacological properties of the antibody when attached to ...
Manufactured by:Mersana Therapeutics based inCambridge, MASSACHUSETTS (USA)
Once ADCs release their cytotoxic payload into targeted cells, the drug is often able to cross cell membranes, entering and potentially killing neighboring cells whether those cells are cancerous or not. This effect is called bystander-killing, which is advantageous when bystander cells are cancerous but toxic if the cytotoxic drug is able to enter adjacent ...
by:Debiopharm based inLausanne, SWITZERLAND
AbYlink™ is an antibody conjugation technology ideally suited for therapeutic and diagnostic applications. Thanks to AbYlink™, cytotoxic or imaging cargos can be selectively attached to the Fc portion of any IgG without prior modification of the antibody. This technology preserves the original affinity of the antibody to its ...
Manufactured by:Qosina based inRonkonkoma, NEW YORK (USA)
H. B. Fuller adhesives are suitable for use in medical devices and certified to the ISO standard 10993-part 5 cytotoxicity. Additional formulations as well as UV light sources for curing are available. Contact our sales team to learn ...
Manufactured by:Qosina based inRonkonkoma, NEW YORK (USA)
Fuller adhesives are designed for general-purpose bonding on all types of substrates and suitable for use in medical devices and certified to the ISO standard 10993-part 5 cytotoxicity. Additional formulations are available. Contact our sales team to learn ...
Manufactured by:The Menarini Group based inFlorence, ITALY
MEN1309 is an antibody-drug conjugate (ADC) constituted by a fully human IgG1 antibody conjugated through a cleavable linker to a cytotoxic agent (a maytansin derivative, DM4), responsible for its antitumor activity. The target antigen, CD205, is highly expressed in a wide range of both solid and hematological cancer cells. Once MEN1309 binds its target, the MEN1309/CD205 complex ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
This drug combines the advantages of two factors: target specificity, which is a characteristic of an antibody, and cytotoxicity, which is a characteristic of a drug. Specifically, this is a technology focused on targeting and killing cancer cells by delivering drugs that cause cytotoxicity to tumor cells using antibodies that can bind to cancer cell-specific ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
Ombipepimut-S Emulsion (DSP-7888) is an investigational immunotherapeutic cancer vaccine containing 2 peptides that induce WT1-specific cytotoxic T lymphocytes (WT1-CTLs) and helper T cells to attack WT1-expressing cancerous cells found in various types of hematologic malignancies and solid tumors.1,2 Researchers have identified that adding helper T-cell–inducing peptides ...
Manufactured by:MV BioTherapeutics SA based inBellinzona, SWITZERLAND
MV010/MV004, in cancer immunotherapy • Significant increase of tumor specific cytotoxic T cells infiltrating the tumor microenvironment by combining MV010/MV004 to anti-PD-L1 administration in murine models. • Significantly improved tumor eradication and resistance to subsequent grafting and improved survival in murine models. ...
Manufactured by:The Menarini Group based inFlorence, ITALY
It comprises human IL-3 recombinantly fused to a truncated diphtheria toxin (DT) payload engineered such that IL-3 replaces the native DT receptor-binding domain. The IL-3 domain of TAGRAXOFUSP directs the cytotoxic DT payload to cells expressing CD123. Upon internalization, TAGRAXOFUSP irreversibly inhibits protein synthesis and induces apoptosis of the target cell. TAGRAXOFUSP ...
Manufactured by:Nanion Technologies GmbH based inMunich, GERMANY
In addition, the base impedance readout is continuously and automatically monitored as a measure of acute and chronic cell activity. No subtleties of cytotoxic responses are missed, this includes non-contractile cell types such as hepatocyte-like cells or cancer cells as well as contractile cardiac cells. Impedance and extracellular field potential measurements are performed at ...
Manufactured by:BioQ Pharma based inSan Francisco, CALIFORNIA (USA)
Our products are thoughtfully-designed to each drug – with bespoke solutions for: Drugs requiring complex weight-based dosing. Cytotoxic drugs. Drugs that need to be reconstituted or diluted at time of use. Drug-drug combinations, including for cold-chain ...
by:Genmab A/S based inCopenhagen V, DENMARK
In preclinical models of hematological malignancies, HexaBody®-CD38 demonstrated enhanced complement-dependent cytotoxicity and potent anti-tumor ...